Update out - no need for panic, page-37

I might be wrong, but the wording of the text suggests

1. The company licences CaPTHymone and BN006 compounds from four subsidiary companies.

I note the word compounds in the sentence which does not represent the final product. I would suggest BNE own the final product on combined format.

2. Bone is in discussions with one of the Group’s subsidiary companies to obtain some interest
in BN006 pending the outcome of the current studies and the parties agreeing terms
acceptable to Bone.

This reads to me like they will sell the product and licencing to one of the subsidiary companies pending outcome of results.

From my quick reading, it would seem BNE do own the final product and that they are looking to sell it. However, no excuses for a very poor announcement. Fortunately I have very very few of these, so will hold and see what develops.